Scienture Secures 180-Day Nasdaq Compliance Extension and Prepares Q2 REZENOPY Launch
Scienture received a 180-day extension until October 12, 2026 to regain Nasdaq’s $1.00 minimum bid price requirement via a reverse stock split or share price increase. The company cites Arbli™ momentum and plans a Q2 2026 REZENOPY™ nasal spray launch as growth drivers.
1. Nasdaq Extension Details
On April 14, 2026 Nasdaq granted Scienture a 180-calendar day extension until October 12, 2026 to regain compliance with the $1.00 minimum closing bid price requirement under Listing Rule 5810(c)(3)(A). This notification has no effect on trading of common stock on the Nasdaq Capital Market.
2. Compliance Strategy and Risks
Scienture meets all continued listing requirements other than bid price and intends to regain compliance by effecting a reverse stock split or other price improvement measures. There is no assurance the company will cure the deficiency within the extension period or maintain other listing criteria.
3. Commercial Momentum from Arbli™
The successful introduction of Arbli™, the first FDA-approved oral liquid losartan for hypertension, has generated meaningful momentum across the commercial portfolio and is expected to drive revenue growth into 2026 and beyond.
4. REZENOPY™ Launch Outlook
Scienture plans to launch REZENOPY™, the highest-dose FDA-approved naloxone nasal spray, in Q2 2026, leveraging its scalable commercial infrastructure to capture a significant market opportunity in opioid overdose treatment.